Buscar
Mostrando ítems 11-17 de 17
Differences in outcome of heart failure with preserved or depressed systolic function in patients older than 70 years who receive beta blockers
(Elsevier, 2011-10-14)
[Abstract] Introduction and objectives. Most studies have shown that prognosis of heart failure with preserved systolic function is as poor as that of heart failure with depressed systolic function, although these results ...
Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry
(Oxford, 2018-10-15)
[Abstract] Aim. To investigate the characteristics long-term prognostic implications (up to ∼2.2 years) of atrial fibrillation (AF) compared to sinus rhythm (SR), between acute and chronic heart failure (HF) with reduced ...
Long‐term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long‐Term Registry
(Wiley, 2017-10-08)
[Abstract] Aims. The aim of this study was to assess long‐term safety of intravenous cardiovascular agents—vasodilators, inotropes and/or vasopressors—in acute heart failure (AHF).
Methods and results. The European Society ...
In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: results from the polish part of the European Society of Cardiology Heart Failure pilot and long-term registries
(Via Medica, 2018-08-29)
[Abstract] Background: Currently, there is no information on whether in-hospital heart rate (HR) reduction has an influence on risk of death or rehospitalization. The study evaluates the relation between inhospital HR ...
Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data From 9222 Chronic Heart Failure Patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
(Willey Online Library, 2020-04-03)
[Abstract]
Aims.
We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death ...
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world
(Wiley, 2019-05-27)
[Abstract] Aims: To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines Agency/Food and Drug ...
Comparison of predicted and observed mortality in patients with heart failure treated at a specialized unit
(Elsevier, 2020-01-21)
[Abstract] Introduction and objectives: To analyze survival in heart failure (HF) patients treated at a specialized unit.
Methods: Prospective cohort-based study of HF patients treated at a specialized unit from 2011 ...